GlassScriptPhysician profile
Aena Patel
NPI 1295152395
$1,320.89
in general payments reported to CMS, 2019-2025
28 companies · $242 in 2025
The $242 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2021: $130 · 2022: $598 · 2024: $130 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $356 · Education: $16.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $355.87 |
| Education | $16.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $349.00 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $123.88 | 2021-2024 | Endopredict |
| Merck Sharp & Dohme LLC | $122.19 | 2019 | |
| Array Biopharma INC | $52.05 | 2025 | Mektovi, Braftovi, Lorbrena |
| Celgene Corporation | $51.74 | 2022-2024 | Reblozyl |
| Genzyme Corporation | $49.67 | 2025 | |
| Coherus Oncology, INC. | $49.35 | 2022 | |
| Novartis Pharmaceuticals Corporation | $39.78 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.84 | 2022-2025 | Fruzaqla |
| Astrazeneca Pharmaceuticals LP | $35.56 | 2022 | |
| Pharmaessentia USA Corporation | $34.84 | 2024 | Besremi |
| Taiho Oncology, INC. | $34.53 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $31.00 | 2025 | Libtayo |
| Dendreon Pharmaceuticals LLC | $30.91 | 2025 | Provenge |
| Adc Therapeutics America, INC. | $26.96 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $24.17 | 2022 | |
| Gilead Sciences, INC. | $22.33 | 2025 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $21.83 | 2022 | |
| Seagen INC. | $21.65 | 2022 | |
| Tempus Ai, INC | $20.33 | 2025 | Xt Cdx |
| Exelixis INC. | $19.40 | 2025 | Cabometyx |
| Tactile Systems Technology INC | $19.05 | 2022 | |
| Daiichi Sankyo INC. | $19.04 | 2022 | |
| Puma Biotechnology, INC. | $18.37 | 2021 | |
| Amgen INC. | $17.19 | 2022 | |
| Kite Pharma, INC. | $16.70 | 2024 | Yescarta |
| Bayer Healthcare Pharmaceuticals INC. | $16.36 | 2022 | |
| Glaxosmithkline, LLC. | $14.17 | 2024 | Ojjaara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aena Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.